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Objective: A systematic review and meta-analysis was conducted to evaluate the agreement between Tuberculin
Skin Test (TST) and Quantiferon (QFT) in screening for tuberculosis (TB) infection among healthcare workers
(HCWs) and to estimate associations between TST and QFT agreement and variables of interest, such as Bacillus
Calmette-Guérin (BCG) vaccination and incidence of TB.
Methods: Cross-sectional and longitudinal studies on HCWs, published in English until October 2013, comparing
TST and QFT results, were selected. For each study Cohen’s κ value and a 95% confidence interval were calculated.
Summary measures and indexes of heterogeneity between studies were calculated.
Results: 29 studies were selected comprising a total of 11,434 HCWs. Cohen’s κ for agreement between TST and
QFT for 24 of them was 0.28 (95% CI 0.22 to 0.35), with the best value in high TB incidence countries and the
lowest rate of BCG vaccination.
Conclusion: Currently, there is no gold standard for TB screening and the most-used diagnostic tools show low
agreement. For evidence-based health surveillance in HCWs, occupational physicians need to consider a number of
factors influencing screening results, such as TB incidence, vaccination status, age and working seniority.
Keywords: Tuberculosis, Tuberculin skin test, Quantiferon TB Gold, Healthcare workers, Health surveillance,
Meta-analysis, Cohen’s kIntroduction
Occupational exposure to biological agents is a major
risk for healthcare workers (HCWs) thus in health sur-
veillance much has to be dedicated to infectious disease
screening. Tuberculosis (TB) is an ongoing risk in low-
income countries due to abandonment of vaccination
campaigns, immigrations flows, wide diffusion of pri-
mary or secondary immunosuppression, poor efficacy of
vaccine currently in use [1,2] so that tuberculosis re-
mains a major public health problem.* Correspondence: rossella.uccello@unina2.it
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unless otherwise stated.According to the World Health Organization (WHO),
in 2012 there were an estimated 8.6 million cases of TB
(range 8.3–9.0 million) globally, equivalent to 122 cases
per 100,000 population. Most of the estimated case num-
bers in 2012 occurred in Asia (58%) and Africa (27%);
smaller proportions occurred in the Eastern Mediterra-
nean region (8%), the European region (4%) and the
Americas (3%). One third of the world’s population is esti-
mated to be latently infected withMycobacterium tubercu-
losis: people with latent TB infection (LTBI) do not show
symptoms of TB and are not infectious, but they are at
risk of developing active disease and becoming infectious.
Several factors increase the risk of progressing from infec-
tion to active TB, for example, HIV infection or immuno-
suppressive treatment, malnutrition, diabetes and alcoholal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tors as well as proper diagnosis and treatment of LTBI in
selected risk groups is thus important for the individual
and for public health [3].
It is clear that LTBI diagnosis is mostly based on screen-
ing programs that address the general population or occu-
pational categories such as healthcare workers. Actually,
there is a lack of gold-standard for LTBI diagnosis: trad-
itionally, TB infection screening is conducted by tubercu-
lin skin testing (TST). Some years ago interferon-gamma
release assays (IGRAs) became commercial available.
IGRAs are used as a confirmatory test for TST in a two
steps procedure or as a replacement of the TST particu-
larly in situations in which the TST is not recommended
[4]. TST remains the major tool used around the world
for diagnosis of TB infection because of well-established
algorithms for test interpretation. In addition TST is easy
to use and it has a good cost-effectiveness. Although
widely used, TST has limitations; its sensitivity may be
reduced by malnutrition, severe TB diseases and immuno-
deficiency. Decreased TST specificity might occur in set-
tings where non-tuberculous mycobacteria (NTM) are
prevalent and in populations who have received Bacillus
Calmette-Guérin (BCG) vaccine post-infancy or via mul-
tiple vaccinations [5], although its effect on TST reactions
could be modest after 10 years. Additionally, completing
the TST requires two healthcare visits, resulting in loss of
reading in approximately 10% of cases [6]. This method is
affected by inter-observer variability and the positive result
does not distinguish recent from remote infection [6].
Most recent national guidelines present IGRAs (espe-
cially Quantiferon, QFT) as a new valid tool for diagnosis
of latent tuberculosis, also because they are ex-vivo blood-
based tests that, in contrast to the TST, can be repeated
any number of times without sensitization or boosting,
they require only one visit and do not need a baseline
two-step protocol [5]. However, reviews have suggested
that IGRA performance differs in high versus low TB
incidence settings as well as in presence of some risk
factors [6]. Moreover, IGRA reproducibility is influ-
enced by several technical factors and immunomodulation
[5]; subsequently, appropriate cut-offs and borderline
zones need jet to be derived especially for interpreting
of IGRA result in serial testing of HCWs in light of an
individual’s tuberculosis risk factors [7]. Although a sin-
gle IGRA is more expensive than the intradermal inves-
tigation, the cost-effectiveness analysis depends on
epidemiological and individual elements, as explained
in several studies that also sought to elaborate specific
models [8].
Several recent systematic reviews showed that HCWs
are at an increased risk of exposure to Mycobacterium
tuberculosis [1,2,9,10]. For this reason, periodic screening
of HCWs is an important component of TB programs,according to the background TB incidence in the popula-
tion, resulting in TB as an occupational disease.
In specific working population, such as HCWs, serial
testing for TB seems to be more appropriate in order to
identify recent infections and to target infected individuals
for preventive therapy [8]. Some guidelines from high-
income low-incidence countries have not recommended
IGRAs for serial testing of HCWs while others state that
IGRAs may be used for serial testing of HCWs in place of
the TST [11]: according to WHO guidelines [12] IGRAs
should not be used in HCW screening programs for low-
and middle-income countries (strong recommendation).
This indication derives from reversion or conversion rates
that reduce IGRA reproducibility.
Until now, there have been various systematic reviews
of literature, evaluating prevalence or incidence of latent
TB disease among HCWs [9] or IGRA performance [11]
for tuberculosis screening in HCWs; agreement between
TST and IGRA has been generally evaluated as second-
ary outcome. A systematic review and meta-analysis had
compared the accuracy of Quantiferon TB Gold in Tube
and the T-SPOT assays with the TST, but has not con-
sidered HCWs and not quantified the agreement be-
tween skin testing and IGRA [13].
The present study aims to conduct a systematic review
with a meta-analysis of the impact of some factors on the
agreement between the two tests (TST and QFT) for TB
screening programs in HCWs, measured with Cohen’s κ in
order to be more rigorous and informative than narrative
and systematic reviews [14,15]. The impact of some risk
factors on the outcome of those tests has also been exam-
ined in order to derive an “evidence-based” protocol for
healthcare workers at risk of tuberculosis.
Methods
Data sources and searches
A systematic review with meta-analysis, according to the
PRISMA (Preferred Reporting Items for Systematic Re-
views and Meta-Analyses) statement, was conducted [16].
Original articles were searched through PubMed,
Embase, Web of Science and Scopus from 1 January
2004 to17 October 2013, using various combinations, in
line with the specific database language, of the terms
“workers” AND “tuberculosis” OR “TB infection” or “TB
disease” OR “TB” AND “tuberculin skin test” OR “tuber-
culin skin testing” AND “Quantiferon”. Additional stud-
ies were taken by means of reference lists from previous
review articles, and citations of relevant original articles
were screened.
Study outcomes and selection
Original articles were evaluated, including cross-sectional
and longitudinal studies, meeting all the following criteria:
screening of LTBI in HCWs with contemporary TST and
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vaccination rates, English language. The following studies
were excluded: duplicates, case reports or studies on close
contacts, editorials, immunological or laboratory studies,
NTM studies. Articles about HCWs affected by HIV,
chronic rheumatological diseases or inflammatory bowel
diseases were also eliminated in order to avoid other influ-
ence factors and to obtain a more homogeneous sample.
Epidemiological studies often did not apply to specific
medical occupational groups, but instead calculated the risk
of infection or disease for the overall group of healthcare
workers with a highly heterogeneous definition of ‘health-
care worker’ that included both occupational groups
with a potentially increased risk and groups without any
contact with tuberculosis patients [10]. In studies physi-
cians, nurses, midwives, laboratory personnel, radiogra-
phers, medical or nursing students were considered as
HCWs; if the authors also included a few contacts or
administrative workers, only data on HCWs was extrap-
olated wherever possible.
Three reviewers (RU, MM, MGLM) independently
screened the citations (title and abstract) identified from
all sources. Subsequently, full-text articles selected by
titles and abstracts were reviewed to identify the final
set of eligible studies. Disagreements were resolved by
discussion.
Data extraction
The following characteristics of each study were listed:
country, publication and screening years, sample size,
type of study, incidence of TB disease in the general
population, gender, mean HCW age, working age, type
of tuberculin used for testing, BCG vaccination rates
(Table 1).
According to several national guidelines, different
types of purified tuberculin proteins (PPD) were used,
PPD RT23 and PPD-S; 5 TU dose of PPD-S (0.1 ml) are
accepted as bio-equivalent to 2 TU of PPD RT23
(0.1 ml) [17].
Different types of QFT have been considered, such as in
the technological development of IFN-γ release assays
over the years: from the first assay, known as Quantiferon-
TB, to the last and more specific Quantiferon-TB-Gold in
Tube (QFT-GIT), that replaced all other types, which are
no longer marketed [18]. In order to provide clear infor-
mation about IGRA/TST agreement, we considered all of
them as “QFT”.
In order to calculate overall agreement between the
two main screening tools, data on TST induration (cut-
off positivity ≥ 10 mm) and QFT positivity (cutoff posi-
tivity 0.35 IU/ml) in HCWs was considered among with
the impact of variables of interest on that agreement
(vaccination rates and TB incidence). In particular, stud-
ies were divided in two groups on the basis of the BCGvaccination rate using different cutoff values because no
reference value was available. The incidence of all forms
of TB disease in the general population were obtained
from the WHO global TB database for each study year,
or publication year, if unavailable. Studies were classified
in three groups based on TB incidence in each country:
low ≤20 cases/100,000, intermediate 21–99 cases/100,000,
and high ≥100 cases/100,000. In order to best characterize
TB incidence, the screening year(s) was/were identified in
each study; studies lasting for two or more years had an
incidence rate calculated by mean.
Any discrepancies were resolved by consensus with the
help of the team coordinator, thus obtaining an inter-
reviewer agreement of 100%.
Data synthesis and analysis
Study characteristics and results are presented in tables
and plots. The primary outcome of the meta-analysis
was the Cohen’s κ. For each study the κ value and 95%
confidence interval (CI) were calculated. Weighted mean
effect size was used as a summary measure. Heterogen-
eity of studies was assessed by using Q statistics and I2
[19]. The P value of Q statistics of less than 0.10 was
considered significant [20]. I2 values of 25%, 50%, and
75% correspond to cutoff points for low, moderate, and
high degrees of heterogeneity. If overall heterogeneity
was significant, a random-effect model was used, other-
wise a fixed-effect model was used. Meta-regression was
applied to test difference of study-level covariates. Meta-
regression is a regression model that relates the effect
to study-level covariates, while assuming additivity of
within-study and between-studies components of vari-
ance. Restricted maximum likelihood estimators were
used to estimate model parameters [21]. A permutation
test (using 1,000 re-allocations) was used to assess the true
statistical significance of an observed meta-regression find-
ing [22]. Data was analyzed using Stata, version 11.0 (Stata
Corp., College Station, TX). All statistical tests were two-
sided and p-values <0.05 were regarded as significant.
Results
Description of included studies
Figure 1 shows the flow chart of the studies selection.
From the initial 1,430 abstracts, 29 studies [23-51] met
our inclusion criteria; 871 studies were discarded as not
concerning HCWs, as expected, because a more sensi-
tive than specific search string was preferred in order to
obtain as many studies of the health sector as possible.
Two hundred and eighty studies were rejected owing to
the lack of all results about agreement between TST and
QFT or about vaccination status; 13 were rejected for
enrolling the same sample of HCWs. Characteristics of
the selected studies in this review are shown in Table 1,
data are presented by TB incidence. Most studies were



























Cross-sectional 4,5 2007-2011 5 U PPD-S 36
Khoury et al.,
2011 [40]
Minnesota, USA 611 Missing data / Start of work
100%






Israel 100 69/31 31 ± 10 y
m + SD
TST-: 3,7 ± 6,1 y
TST+: 8,7 ± 10,1 y
QFT-: 4,6 ± 7,3 y
QFT+: 4,2 ± 5,8 y
m + SD
Prospective 5,8 2007 5 U PPD-S 37
Vinton et al.,
2009 [29]
Australia 481 431/50 42 (20–66) y
M(range)
/ Cross-sectional 6 2008 10 U PPD-S 78
Larcher et al.,
2012 [46]
Italy 549 397/152 38,3 (19–64) y
m(range)






Germany 261 212/49 40 ± 10,4 y
m ± SD
/ Cross-sectional 4,5 2006 2 U PPD-RT23 38
Soborg et al.,
2007e [23]
Denmark 139 115/24 <30 y 17%
30–39 y 30%
40–49 y 33%
≥ 50 y 20%
/ Cross-sectional 6,5 2007 2 U PPD-RT23 76
Girardi et al.,
2009 [31]
Italy 115 67/48 ≤41 y 51%
>41 y
49%
/ Cross-sectional 2,8 2004-2005 5 U PPD-S 37
Freeman et al.,
2012e [47]
New Zealand 325 270/55 18-30 y 49,2%
31–50 y 41,8%
51–60 y 8,9%










≤10 y 52,7% >
10 y 47,3%




et al., 2009 [33]
Spain 134 101/33 33,4 ± 9,4 y
m ± SD
10,8 ± 8,2 y
m ± SD
Cross-sectional 15 2007 2 U PPD-RT23 35
Casas et al.,
2009 [34]




Cross-sectional 15 2004-2005 2 U PPD-RT23 16
Talebi-Taher
et al., 2011 [41]



































Table 1 Characteristics of studies (Continued)
Hotta et al.,
2007e [24]
Japan 207 132/75 20 (18–42) y
M(range)





Croatia 54 51/3 44 (21–63) y
m(range)
/ Cross-sectional 17 2007 2 U PPD-RT23 100
Ozdemir et al.,
2010e [38]
Turkey 76 33/43 30,4 ± 5,4 y
m + SD
3,9 ± 4,7 y
m ± SD
Cross-sectional 24 2005 5 U PPD-S 91
Torres Costa
et al., 2011 [42]











Cohort 24 2007 2 U PPD-RT23 100
Rafiza et al.,
2011 [43]
Malaysia 953 839/114 <24 y 30,7%
25–29 y 35,2%
30–34 y 15,6%
> 35 y 18,5%
<1 y 14% 1–5 y
47% 6–10 y 17,5%
≥ 11 y 21,5%
Cross-sectional 81 2008-2009 2 U PPD-RT23 100
Choi et al.,
2008 [26]




Cross-sectional 100 2006 2 U PPD-RT23 100
Lee et al.,
2009 [36]
South Korea 196 196/0 23,4 ± 1,4 y
m + SD
/ Prospective 100 2007 2 U PPD-RT23 93
Lee et al.,
2010 [39]




Cross-sectional 100 2009-2010 2 U PPD-RT23 100
Moon et al.,
2011 [44]




Cross-sectional 100 2010 2 U PPD-RT23 100
Jung et al.,
2012 [48]
South Korea 153 48/105 21.9 ± 0.9 y
m + SD
/ Cross-sectional 108 2010-2012 2 U PPD-RT23 86
Jo et al.,
2013 [50]
South Korea 493 383/110 30,6 ± 6,0 y
m + SD
<1 y 8,3% 1–5 y
49,7% 6–10 y 23,1%
11–15 y 13,8%≥
15 y 5,1%
Cross-sectional 100 2012 2 U PPD-RT23 81
Whitaker et al.,
2013 [51]





0-4 y 22% 5–14 y
26% 15–24 y 23%
≥ 25 y 29%
Prospective 125 2009-2011 5 U PPD-S 90
Mirtskhulava
et al., 2008 [27]
Georgia 265 229/36 42 (18–74) y
m(range)
8 (1–42) y M (range) Cross-sectional 125 2006 5 U PPD-S 78
Lien et al.,
2009 [37]
Vietnam 265 197/68 40 (20–58) y
M(range)
<2 y 11% ≥2 < 5 y
17,7% ≥5 < 10 y
16,6% ≥10 y 54,7%






























Table 1 Characteristics of studies (Continued)
Pai et al.,
2008 [28]
India 719 446/273 22 y M / Cohort 249 2004 212 1 U PPD-RT23 71
He et al.,
2012 [49]
Mongolia 917 659/258 18-29 y 22%
30–39 y 23%
40–49 y 35%
≥ 50 y 20%
10 (<1-50) y
M(range)
Cross-sectional 223 2010 224 5 U missing data 34
aData shown through mean (m) + standard deviation (SD) or through mean (m) and range or through Median (M) and range or through percentage (%); / = missing data. Data are shown in months (m) or years (y).
bAccording to WHO data 2012, rates for 100.000 population.
cAccording to WHO data for each screening year, rates for 100.000 population.
dAccording to data reported in each study or cited national guidelines.














Figure 1 Flow-chart of studies selection. From the initial 1430 abstracts, 29 studies met our inclusion criteria. Study sizes ranged from 54 to
2884 HCWs, for a total of 10.314 HCWs across the 29 studies.
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information was taken. Study sizes ranged from 54 to
2,884 HCWs, for a total of 11,434 HCWs across the 29
studies. In total, there were 8,098 female and 2,725 male
workers; for 611, gender was not indicated [40].
The age mostly represented in the sample was between
30 and 50 or between 18 and 30 when students were in-
cluded. The overall mean or median age could not be
calculated because the sample age was differently re-
ported in the studies as mean, median or percentage.
Working seniority was defined by the number of years
or months spent in contact with patients: it played an im-
portant role in TB screening results, but in 11 studies data
was not shown; in the other 18, this information was het-
erogeneous (reported through mean, median or percent-
age). Therefore as with age a mean or median for working
seniority could not be calculated; one study carried out apre-employment evaluation in a healthcare occupational
surveillance program [40].
Skin testing was conducted using different types and
doses of tuberculin: the dose varied from 1 to 10U ac-
cording to the national guideline. TST was performed
using 2U of RT23 in most studies (14/29) while in 12/29
5U of PPD-S were used.
Among the 29 selected studies, 24 used 10 mm as cut-
off for positivity [26-37,39-46,48-51], 2 of them reported
15 mm [24,38], other 2 studies considered 5 mm [25,47]
and in only one was the cutoff 12 mm [23]. In order to
calculate overall agreement, we considered only studies
with 10 mm as cutoff positivity. BCG vaccination rates
run from 16 to 100%, with a median of 81%.
On the basis of TB incidence identified by WHO infor-
mation for each year of screening, studies were divided into
three groups of incidence: the low TB incidence group was
Lamberti et al. Journal of Occupational Medicine and Toxicology  (2015) 10:2 Page 8 of 13the most represented, being included in 10 studies, followed
by the intermediate group with 7 studies and the high
group with 7 studies (Figure 2). In a few cases, there was a
relevant difference between the two incidence rates
[31,32,46,35] owing to a delay in publication.
Agreement between TST and QFT
Table 2 shows data by TB incidence on subjects with both
TSTand QFT results, excluding indeterminate QFT results;
for this reason the effective sample size was 10,314, or
lower than in Table 1.Figure 2 Meta-analysis of Cohen’s k values for agreement between T
by Tuberculosis (TB) infection incidence classes. In order to calculate o
positivity. ES: k value.Screening results were reported as positive TST alone,
positive QFT alone and crossed of TST and QFT. Out of
the 10,314 tests performed, TST and QFT agreed for
6,893 of them and failed to do so for 3,421. TST positive
QFT negative discordance occurred about four times
more often than TST negative QFT positive discordance
[2,711 (26.3%) versus 710 (6.9%)].
In order to evaluate TST and QFT agreement, a statis-
tical analysis was conducted using Cohen’s κ in each
study. However, only for 24/29 studies, which used a
TST positivity cutoff at 10 mm, overall agreement wasuberculin Skin Test (TST) and Quantiferon TB Gold-In-Tube (QFT)
verall agreement, we considered only studies with 10 mm as cutoff
Table 2 Comparison of TST and QFT results in healthcare workers from different studies
First author Sample size (n) TST+ (n) QFT+ (n) TST+/QFT+ (n) TST+/QFT- (n) TST-/QFT+ (n) TST-/QFT- (n)
Zwerling et al., 2012 [45] 387a 22 24 7 15 17 348
Khoury et al., 2011 [40] 611 50 12 8 42 4 557
Fox et al., 2009 [30] 91a 31 17 9 22 8 52
Vinton et al., 2009 [29] 341a 114 21 16 98 5 222
Larcher et al., 2012 [46] 549 160 81 57 103 24 365
Nienhaus et al., 2008b [25] 261 63 25 15 48 10 188
Soborg et al., 2007b [23] 139 47 2 2 45 0 92
Girardi et al., 2009 [31] 115 61 40 36 25 4 50
Freeman et al., 2012b [47] 317a 67 28 19 48 9 241
Tripodi et al., 2009 [32] 148 97 51 23 74 5 46
Alvarez-Leon et al., 2009 [33] 123a 9 8 5 4 3 111
Casas et al., 2009 [34] 145a 101 43 42 59 1 43
Talebi-Taher et al., 2011 [41] 200 105 17 14 91 3 92
Hotta et al., 2007b [24] 202a 120 3 3 117 0 82
Topic et al., 2009 [35] 54 34 17 15 19 2 18
Ozdemir et al., 2010b [38] 76 41 65 39 2 26 9
Torres Costa et al., 2011 [42] 2,884 2,102 953 850 1252 103 679
Rafiza et al., 2011 [43] 95a 56 13 11 45 2 37
Choi et al., 2008 [26] 80 36 16 13 23 3 41
Lee et al., 2009 [36] 196 93 28 22 71 6 97
Lee et al., 2010 [39] 82 31 19 10 21 9 42
Moon et al., 2011 [44] 156a 52 32 18 34 14 90
Jung et al., 2012 [48] 153 23 8 6 17 2 128
Jo et al., 2013 [50] 493 181 85 54 127 31 281
Whitaker et al., 2013 [51] 260a 145 112 90 55 22 93
Mirtskhulava et al., 2008 [27] 265 177 159 133 44 26 62
Lien et al., 2009 [37] 255a 163 135 114 49 21 71
Pai et al., 2008 [28] 719 298 288 226 72 62 359
He et al., 2012 [49] 917 439 638 350 89 288 190
Total 10,314 4,918 2,940 2,207 2,711 710 4,686
awe consider only subjects with both TST and QFT results, excluding undeterminate quantiferon results.
bStudies not included in the meta-analysis.
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to 0.61, with a significant heterogeneity (p < 0.0001, I2 =
91.6%). Overall κ value, estimated using the random ef-
fect model, was 0.28 (95% CI 0.22 to 0.35), which is
quite low reflecting that almost one third of TST and
QFT results were discordant (Table 2).
Association between κ value and variables of interest
Studies were classified according to type and dose of
PPD. No significant difference (p = 0.717) was found be-
tween studies with <5 TU (κ = 0.27, 95% CI 0.17 to 0.37)
versus ≥5 TU (κ = 0.29, 95% CI 0.21 to 0.38).
According to TB incidence classification, TST and
QFT agreement was calculated with Cohen’s κ resultingin 0.25 (95% CI 0.17 to 0.34) in the low incidence group,
0.19 (95% CI 0.17 to 0.21) in the intermediate, and 0.38
(95% CI 0.23 to 0.53) in the high group. The best agree-
ment was observed in the high incidence group, while
the worst was seen in the intermediate one, with the
highest rate of vaccination; comparing the three κ fig-
ures there was a significant difference between the inter-
mediate and the high incidence group (p = 0.041).
Furthermore, studies were divided in two groups (lower
and higher vaccination rate) to best elucidate BCG vac-
cination impact on agreement; considering a 90% cutoff
value as a statistically significant difference (p = 0.013)
was found, with an agreement of 0.34 (95% CI 0.25
to 0.43) in the lower rate group (15 studies), and 0.17
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(Figure 3).
Discussion
This meta-analysis had the aim of analyzing screening
tools for diagnosis of TB infection among HCWs and
examining the impact of some risk factors on the out-
come of those tests in order to derive an “evidence-
based” protocol for screening of healthcare workers at
risk of tuberculosis. As already highlighted [11], overall
agreement between TST and QFT was quite low. This re-
sult can be related to the different immunological targets
of the two tests, so that any immunological dysfunction
can variously influence their respective results. Moreover,Figure 3 Meta-analysis of Cohen’s k values for agreement between T
by Bacillus Calmette-Guérin (BCG) vaccination groups. ES: k value.QFT is often characterized by fluctuating results so that
its reproducibility is unclear [52]; on the other hand, TST
has an inter-observer variability.
TST and QFT also differ in specificity and sensitivity.
A lower rate of positivity in the QFT can be explained
by a higher specificity of QFT than TST that could come
from the intrinsic difference in the methods used by the
two tests. QFT uses antigens showing higher specificity
to Mycobacterium tuberculosis and to only a limited
number of NTM, in contrast with the tuberculin used
in TST, which represents a mixture of more than 200
nonspecific antigens shared with NTM and with the
strains developed from Mycobacterium bovis used for
BCG vaccination [53].uberculin Skin Test (TST) and Quantiferon TB Gold-In-Tube (QFT)
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was the high heterogeneity of the studies chosen owing
to different impact of each variable (vaccination rates,
incidence of TB in each country, age, working seniority,
induration diameter cutoff and type of PPD) on the
TST/QFT agreement. Again, this variability could be
considered as a strength of the study because it offered
an opportunity to best elucidate the agreement, taking
these factors into account.
BGC vaccination status and incidence of TB, influencing
TST and QFT agreement at the same time, could not be
valued separately. BCG vaccination reduced the agree-
ment, influencing the TST positivity (rather than QFT
positivity) and increasing the risk of a false positive result,
especially in recently vaccinated subjects. Although some
studies [29,45,47,34] showed a QFT positivity amount
lower than the TST positivity one, in the BCG vaccinated
group, this result could not be explained with a cross-
reaction between vaccination and QFT antigens, but with
a TB infection among vaccinated subjects. In the high TB
incidence group, a vaccination status lower than 90% was
found and, at the same time, the higher observed agree-
ment, although two studies in particular contributed to
the decrease of the agreement [49,50]; in detail, some au-
thors found high rates of TST-/QFT+ [49] and others
found high rates of TST+/QFT- [50]. In the first case, the
result could be explained by a high TB risk ward and a his-
tory of TB infection for some subjects; in the other study,
false positive results can be explained by re-vaccination.
Some authors also affirmed that repeated vaccination
influenced quantitative TST positivity but decreased a
probability of positive QFT in the case of three or more
repeated doses [42]. Moreover, in the low TB incidence
group, studies with higher agreement were characterized
by the lower rate of vaccination.
Increasing age of HCWs is correlated with concordant
TST and QFT positive results [33,34]; Discordant QFT
positive TST negative results were associated with an
age of over 40 [46,50] or over 50 [49,42] and anyhow
this association increased each year [39], although data
was not statistically elaborated due to heterogeneity of
presentation.
In consideration of working seniority and TST/QFT
results, most studies [27,44,42,49] found an association
between increasing working years and positivity of both
tests; this information cannot be accounted for alone but
it has to be contextualized in the risk evaluation at each
worksite (high or low TB risk ward). However, in this re-
view there was no statistical analysis of overall age or
working seniority possible because of heterogeneity of
data presentation or missing information.
Among the studies considering 10 mm and 15 mm
as cutoff diameters, three showed better agreement
when shifting TST cutoff from 10 mm to 15 mm[29,35,43]; instead, in five studies there was no mean-
ingful difference [33,24,26,44,27].
Some authors affirmed that the type of tuberculin
could play a significant effect on skin response: both vac-
cinated and unvaccinated subjects receiving RT23 2 TU
or 1TU were more likely to have a positive result than
those receiving 5 TU PPD [54]. Others [55] considered
that TST induration size was larger with PPD-S than
with PPD RT23 at 48, 72 and 96 hours, resulting in a
statistically lower number of false negatives with PPD-S
than with PPD RT23. Despite this evidence, no signifi-
cant difference was found between various types and
doses of tuberculin in the chosen studies, confirming
bio-equivalence of RT23 and PPD-S [17].
Study limitations and strength
This systematic review has several strengths. A more
sensible than specific search string was elaborated, using
multiple databases. Three reviewers (RU, MM, MGLM)
independently assessed eligible articles for inclusion. Se-
lection criteria were quite restrictive, so that information
obtained was as comparable as possible in order to
realize a meta-analysis of overall agreement between the
two main screening tools and the influence of some fac-
tors (BCG vaccination, TB incidence). However, this was
not possible for other variables of interest (age and
working seniority) owing to heterogeneity in study de-
sign, outcomes and data presentation, despite the limited
selection. Still, different national guidelines contribute
different study characteristics, particularly on TST pro-
cedures and vaccine indications. Lastly, there was a lack
of evidence at the highest level of hierarchy on reference
standards: a majority of the studies included were cross-
sectional. Our study would have appeared more relevant
if we had considered longitudinal studies and TST/QFT
agreement in serial testing, analyzing all factors that
could impact on reversion and conversion. Nevertheless,
longitudinal studies did not allow us to analyze both
tests in each measurement because it is not always ap-
propriate to repeat both TST and QFT in every HCW.
Conclusion
Screening for TB infection is a major objective of health
surveillance programs. Nowadays, even if there is no
gold standard, the most-used diagnostic tools are TST
and IGRAs (such as QFT) that show a low agreement
and are also influenced by few variables that partially
justify their variability alone.
Choosing the proper protocol is a prerogative of the
occupational physician, who needs to know about TB
and BCG vaccination incidence in the general popula-
tion and the immunological status and risk factors for
each individual worker. TST remains the first-step exam,
especially when a higher agreement can be expected, i.e.
Lamberti et al. Journal of Occupational Medicine and Toxicology  (2015) 10:2 Page 12 of 13when there is a low prevalence of vaccination or a high
incidence of TB infection. Indeed, QFT is helpful in
cases of a higher prevalence of vaccination. Further
studies with a unique protocol of health surveillance car-
ried out in variously burdened countries will best clarify
the role of TST and QFT for HCW screening.
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